Company intelligence / Profile preview

Rubicon Genomics

Ann Arbor, Michigan, United Statestakarabio.com ↗

Ownership: Private
Employees: ~40
Development stage: Commercial

Overview

Rubicon Genomics developed proprietary technologies for preanalytical amplification of nucleic acids from challenging samples. Their platforms enabled robust genome-wide genotyping, haplotyping, and next-generation sequencing library preparation. The company’s products were widely adopted in research and clinical labs prior to its acquisition by Takara Bio USA Holdings in 2017.

Modalities: DNA amplification technologyNucleic acid library preparation kits
Industry: Molecular Diagnostics

Partnerships

Agilent Technologies – supply agreement for amplification kits used in reproductive health testingCurio Genomics – comarketing agreement for bioinformatics software with ThruPlex Tag-seq kitMultiple academic collaborations reported historically

Beyond the preview

Go deeper on Rubicon Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rubicon Genomics.

Explore the full profile